Nov. 12 at 3:32 PM
Shares of DBV Technologies rose in premarket trading Wednesday after the clinical-stage biopharma company announced it has completed the final patient visit in its Phase 3 VITESSE trial of the VIASKIN Peanut patch.
The trial is assessing the safety and efficacy of the VIASKIN Peanut patch in children aged 4–7 with peanut allergies. With the completion of the double-blind, placebo-controlled treatment phase, DBV is on track to release the VITESSE top-line data in Q4 2025.
“The final visit of the last patient marks a very important milestone for DBV, bringing us one step closer to potentially offering this treatment option to peanut-allergic children, their physicians, and caregivers, if approved,” said CEO Daniel Tassé.
The Phase 3 VITESSE trial includes 654 subjects randomized 2:1 across 86 centers in the U.S., Canada, Europe, the U.K., and Australia. DBV notes it is currently the largest interventional treatment study in peanut allergy.
$DBVT